Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-23T07:53:03.973Z Has data issue: false hasContentIssue false
  • English
  • Français

53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression

Part of: JCTS_2023_ABSTRACT_COLLECTION

Published online by Cambridge University Press:  24 April 2023

Harriet T Rothschild ,
A Jo Chien ,
Rachel C Jankowitz ,
Mark JM Magbanua ,
Jason A Mouabbi ,
Rebecca A Shatsky ,
Julia Levine  and
Rita A Mukhtar
Harriet T Rothschild
Affiliation:
School of Medicine, University of California, San Francisco
A Jo Chien
Affiliation:
Department of Medicine, University of California, San Francisco
Rachel C Jankowitz
Affiliation:
Department of Medicine, University of Pennsylvania
Mark JM Magbanua
Affiliation:
Department of Laboratory Medicine, University of California, San Francisco
Jason A Mouabbi
Affiliation:
Department of Breast Medical Oncology, MD Anderson Cancer Center
Rebecca A Shatsky
Affiliation:
Department of Medicine, University of California, San Diego
Julia Levine
Affiliation:
Lobular Breast Cancer Alliance
Rita A Mukhtar
Affiliation:
Department of Surgery, University of California, San Francisco
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: We are launching a multi-center prospective registry for patients with metastatic invasive lobular carcinoma (ILC), the second most common type of breast cancer, to better understand patterns of progression, imaging features of metastatic sites, and if serial cell free DNA measurements can serve as a surrogate marker of disease progression. METHODS/STUDY POPULATION: Patients with biopsy proven metastatic ILC of any receptor subtype will be included in the registry. We will exclude patients with ductal histology only or those with multiple primary malignancies. Patients will be enrolled at four large academic medical centers across the country. Cell free DNA measurements using a tumor informed assay will be obtained every 3 months concurrent with regular clinical imaging. Disease status will be determined by the patient’s medical oncologist by taking into account imaging, tumor markers, symptoms, and cell free DNA measurement. At each time point, patients will be surveyed on their quality of life and their medical oncologists will be asked to rate the clinical utility of the cell free DNA value. Patients will be followed indefinitely. RESULTS/ANTICIPATED RESULTS: We will explore whether the use of serial cell free DNA or a combination of blood-based biomarkers and clinical endpoints can reliably identify treatment response and disease progression in patients with metastatic ILC. Many patients with metastatic ILC have unmeasurable disease on imaging and are thereby excluded from clinical trials. The end goal of this registry is to determine if blood-based biomarkers can be used as a proxy for measurable disease in ILC patients and therefore increase clinical trial enrollment for this subgroup of patients. DISCUSSION/SIGNIFICANCE: The creation of this prospective registry will open the door for future studies of blood-based markers that reflect disease stability and progression, which is an unmet need specifically in ILC. Identification of such markers could lead to a novel treatment response endpoint, changing the way patients are enrolled in trials and managed clinically.

Type
Biostatistics, Epidemiology, and Research Design
Information
Journal of Clinical and Translational Science , Volume 7 , Issue s1 , April 2023 , pp. 14
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2023. The Association for Clinical and Translational Science

Footnotes

†

The author list and their affiliations have been amended since original publication. A corrigendum detailing these changes has been published at doi: 10.1017/cts.2023.637.